JPMorgan Chase & Co. Raises Stock Holdings in Inhibrx, Inc. (NASDAQ:INBX)

JPMorgan Chase & Co. raised its position in shares of Inhibrx, Inc. (NASDAQ:INBX) by 47.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,592 shares of the company’s stock after buying an additional 2,457 shares during the quarter. JPMorgan Chase & Co. owned about 0.05% of Inhibrx worth $117,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. PNC Financial Services Group Inc. bought a new stake in Inhibrx in the fourth quarter worth $28,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Inhibrx in the 4th quarter worth about $47,000. New York State Common Retirement Fund bought a new position in Inhibrx in the 4th quarter worth about $53,000. Corebridge Financial Inc. purchased a new stake in Inhibrx during the 4th quarter valued at about $89,000. Finally, Exchange Traded Concepts LLC bought a new stake in Inhibrx during the 4th quarter valued at about $148,000. Institutional investors own 82.46% of the company’s stock.

Inhibrx Stock Performance

Shares of Inhibrx stock opened at $12.33 on Tuesday. Inhibrx, Inc. has a twelve month low of $10.80 and a twelve month high of $34.75. The company’s 50 day moving average is $12.96 and its 200 day moving average is $13.90.

Inhibrx (NASDAQ:INBX) last released its quarterly earnings results on Monday, March 17th. The company reported ($3.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21). The business had revenue of $0.10 million during the quarter. Equities analysts expect that Inhibrx, Inc. will post 104.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.